2-苯基喹啉-4-羧酸乙酯 | 4420-46-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-苯基喹啉-4-羧酸乙酯
• 英文名称: ethyl 2-phenylquinoline-4-carboxylate
• CAS: 4420-46-6
• 化学式: C₁₈H₁₅NO₂
• 分子量: 277.323
• InChiKey: BUQNPWJQTNKRJA-UHFFFAOYSA-N

物化性质

• 熔点：
  58-59 °C(Solv: ethanol (64-17-5))
• 沸点：
  441.5±33.0 °C(Predicted)
• 密度：
  1.172±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : ETHYL 2-PHENYL-4-QUINOLINECARBOXYLATE
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 4420-46-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Chronic aquatic toxicity (Category 4), H413
For the full text of the H-Statements mentioned in this Section, see Section 16.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram none
Signal word none
Hazard statement(s)
H413 May cause long lasting harmful effects to aquatic life.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C18H15NO2
Molecular Weight : 277,33 g/mol
CAS-No. : 4420-46-6
No components need to be disclosed according to the applicable regulations.
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 4,41
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苯基喹啉-4-羧酸乙酯 在 一水合肼 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 30.0h， 生成 4-amino-5-cinchophenyl-3-thiohydroxy-1,2,4-triazole
  参考文献：
  名称：

  含辛可芬的三唑类、恶二唑类和稠合杂环化合物的合成及代表性化合物的生物活性研究

  摘要：

  化合物 2-arylamino-5-cinchophenyl-1,3,4-oxadiazoline (7) 和 3-thio-4-amino-5-cinchophenyl-1,2,4-triazole (3) 已使用 cinchophen 作为起始合成材料。化合物 3-cinchopheny-s-triazolo[3,4-b]-1,2,3,4-thiatriazole (4) 由化合物 3 制备。在 POCl 3 存在下，3 与芳香酸缩合得到 10 6-aryl-3-cinchopheny-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (5)。筛选了一些代表性化合物的抗菌活性。这些新化合物的结构已通过元素分析、IR、1 H NMR和MS得到证实。

  DOI：

  10.1002/jccs.200400049
• 作为产物：
  描述：

  2-苯基-4-喹啉羧酸 在 乙醇 、 硫酸 作用下， 生成 2-苯基喹啉-4-羧酸乙酯
  参考文献：
  名称：

  结核病的化学贡献I.亲水性，亲水性和亲水性延伸物的应用

  摘要：

  为了找到新的抗结核化合物，遵循了一个新的构想，制备了一些在2位取代的金鸡尼克酸系列的酰肼和。

  DOI：

  10.1002/hlca.19530360628

文献信息

• Synthesis and the keto-enol equilibrium of 2-acyl lactams
  作者：V. G. Nenajdenko、A. M. Gololobov、E. P. Zakurdaev、E. S. Balenkova

  DOI：10.1023/b:rucb.0000012373.06094.ff

  日期：2003.11

  Condensation of N-substituted lactams with carboxylic acid esters was studied. A wide range of substituted 2-acyl lactams with different ring sizes were synthesized. The structure of 2-acyl lactams (primarily, the ring size) was found to influence the keto-enol tautomerism.

  研究了 N-取代内酰胺与羧酸酯的缩合反应。合成了多种具有不同环大小的取代 2-酰基内酰胺。发现 2-酰基内酰胺的结构（主要是环大小）影响酮-烯醇互变异构。
• Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases
  作者：Aliaa M. Mohassab、Heba A. Hassan、Dalia Abdelhamid、Ahmed M. Gouda、Bahaa G.M. Youssif、Hiroshi Tateishi、Mikako Fujita、Masami Otsuka、Mohamed Abdel-Aziz

  DOI：10.1016/j.bioorg.2020.104510

  日期：2021.1

  New quinoline / chalcone hybrids containing 1,2,4-triazole moiety have been designed, synthesized and their structures elucidated and confirmed by various spectroscopic techniques. The designed compounds showed moderate to good activity on different NCI 60 cell lines in a single-dose assay with a growth inhibition rate ranging from 50% to 94%. Compounds 7b, 7d, 9b, and 9d were the most active compounds

  已经设计、合成了含有 1,2,4-三唑部分的新型喹啉/查耳酮杂化物，并通过各种光谱技术阐明和确认了它们的结构。设计的化合物在单剂量试验中对不同的 NCI 60 细胞系显示出中等至良好的活性，生长抑制率为 50% 至 94%。化合物7b、7d、9b和9d是大多数癌细胞系中活性最强的化合物，其生长抑制百分比在 77% 和 94% 之间。评估了新合成的杂交体对一组四种人类癌细胞系的抗增殖活性。化合物7a、7b、9a、9b和9d显示出有希望的抗增殖活性。以厄洛替尼作为参考药物，进一步测试了这些化合物对 EGFR 和 BRAF V600E激酶的抑制效力。化合物7a、7b、9a、9b和9d的分子对接研究表明，它们非常适合 EGFR 和 BRAF V600E激酶的活性位点。化合物7b、9b和9d显示出最高的结合亲和力和与厄洛替尼相似的结合模式。
• Rapid synthesis of quinoline-4-carboxylic acid derivatives from arylimines and 2-substituted acrylates or acrylamides under indium(iii) chloride and microwave activations. Scope and limitations of the reaction
  作者：Dorothée Duvelleroy、Cécile Perrio、Olivier Parisel、Marie-Claire Lasne

  DOI：10.1039/b509400c

  日期：——

  quinoline-4-carboxylic acid derivatives has been achieved by reaction of 2-methoxy acrylates or acrylamides with N-arylbenzaldimines in acetonitrile under InCl3 catalysis and microwave irradiation. Isolated yields up to 57% within 3 min have been obtained. The Lewis acid and the microwave activation appeared as crucial parameters for the reaction. The role of indium chloride and ytterbium triflate was specified

  在InCl3催化和微波辐射下，2-甲氧基丙烯酸酯或丙烯酰胺与N-芳基苯甲二胺在乙腈中的反应已实现了喹啉-4-羧酸衍生物的快速合成。在3分钟内获得了高达57％的分离产率。路易斯酸和微波活化似乎是反应的关键参数。使用13 C NMR数据和模型理论研究确定了氯化铟和三氟甲磺酸的作用。
• New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity
  作者：Samar H. Abbas、Amer Ali Abd El-Hafeez、Mai E. Shoman、Monica M. Montano、Heba A. Hassan

  DOI：10.1016/j.bioorg.2018.10.064

  日期：2019.2

  A series of quinoline-chalcone hybrids was designed as potential anti-cancer agents, synthesized and evaluated. Different cytotoxic assays revealed that compounds experienced promising activity. Compounds 9i and 9j were the most potent against all the cell lines tested with IC50 = 1.91-5.29 µM against A549 and K-562 cells. Mechanistically, 9i and 9j induced G2/M cell cycle arrest and apoptosis in both

  设计了一系列喹啉-查耳酮杂化物作为潜在的抗癌药，进行了合成和评估。不同的细胞毒性试验表明，化合物具有良好的活性。化合物9i和9j对所有测试的A549和K-562细胞的IC50 = 1.91-5.29 µM的细胞系最有效。从机理上讲，9i和9j诱导了A549和K562细胞的G2 / M细胞周期停滞和凋亡。此外，当针对两种提及的化合物进行测试时，所有PI3K亚型均被非选择性抑制，IC50为52-473 nM，其中9i对PI3K-γ最有效（IC50 = 52 nM）。9i和9j的对接显示可能在PI3K-γ同工型的活性位点与基本缬氨酸残基形成H键。同时，Western印迹分析显示9i和9j抑制了PI3K，Akt，mTOR，以及A549和K562细胞中的GSK-3β，提示阻断PI3K / Akt / mTOR途径与上述抗肿瘤活性相关。总之，我们的发现通过抑制PI3K / Akt / mTOR途径，支
• Synthesis and evaluation of antibacterial and antioxidant activity of novel 2-phenyl-quinoline analogs derivatized at position 4 with aromatically substituted 4<i>H</i>-1,2,4-triazoles
  作者：Donatella Verbanac、Ritu Malik、Mahesh Chand、Khushbu Kushwaha、Monika Vashist、Mario Matijašić、Višnja Stepanić、Mihaela Perić、Hana Čipčić Paljetak、Luciano Saso、Subhash C. Jain

  DOI：10.1080/14756366.2016.1190714

  日期：2016.11.2

  detailed spectral analysis utilizing different techniques such as IR, 1H NMR, 13C NMR, and finally mass spectrometry. All the synthesized compounds were evaluated in vitro for their potential antibacterial activity and their preliminary safety profile was assessed through cytotoxicity assay. Additionally, six selected conjugates were evaluated for their antioxidative properties on the basis of density

  以2-苯基喹啉-4-羧酸为起始原料，分三步合成了一组新颖的喹诺酮-三唑共轭物（12-31）。所有中间体，以及最终的1,2,4-三唑基喹啉都通过使用不同的技术（例如IR，1H NMR，13C NMR和最后的质谱）进行详细的光谱分析而得到充分表征。在体外评估所有合成的化合物的潜在抗菌活性，并通过细胞毒性测定评估其初步的安全性。此外，基于密度泛函理论计算，使用自由基清除测定法（DPPH）和细胞抗氧化剂测定法，对6种选定的缀合物的抗氧化性能进行了评估。